Decentriq LogoViralGains Logo

Audience Identity & Clean Rooms · vs · Third-Party Audience Targeting Segments

Decentriq vs ViralGains

Structured technology and market comparison · 2026

Direct Feature Comparison

Decentriq · vs · ViralGains
Direct Feature Comparison: Decentriq vs ViralGains
Attribute
Decentriq LogoDecentriq
ViralGains LogoViralGains
Market Cluster / SectorAudience Identity & Clean RoomsThird-Party Audience Targeting Segments
Business Model / RoleAdTech VendorAdTech Vendor
Platform FocusPrivacy-first clean room software for secure data collaboration and activation.Privacy-first adtech for zero-party data capture and activation.
Company Size10–49 employees50–200 employees
HeadquartersSwitzerlandUnited States
Year Founded20192012
Dossier & Alternatives

Analyze all overlapping signals and tech stacks for Decentriq and ViralGains

Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.

Compare in PlatformInstant access · 1-click via Google/LinkedIn

Comparison Analysis

What is the main difference between Decentriq and ViralGains?

When comparing Decentriq and ViralGains, both platforms operate within the Customer Data & Clean Room Platform (CDP/DCR), Connected TV (CTV) & OTT, and Display Ads & Banner ecosystem. Decentriq is positioned as Privacy-first clean room software for secure data collaboration and activation, whereas ViralGains focuses on Privacy-first adtech for zero-party data capture and activation. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.

What are the top alternatives to Decentriq and ViralGains?

When evaluating Decentriq and ViralGains, enterprise buyers also consider other platforms in Customer Data & Clean Room Platform (CDP/DCR), Connected TV (CTV) & OTT, and Display Ads & Banner. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.

How do the corporate scale, structure, and headquarters of Decentriq and ViralGains compare?

Decentriq is headquartered in Switzerland (founded in 2019) with 10–49 employees. ViralGains is based in United States (founded in 2012) with 50–200 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.

Market Signals

Recent Market Signals & Activity: Decentriq vs ViralGains

Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.

Decentriq Logo

Decentriq

Recent Signals

  • ·PurpleLabProduct & Platform Launch

    PurpleLab Recognized as a 2026 AdExchanger Awards Finalist in Measurement and Analytics

    PurpleLab announced on September 25, 2026 that it has been named a finalist in the 2026 AdExchanger Awards in the Best Measurement or Analytics Capability category. The company highlights recent launches including a HealthNexus measurement suite, a social media measurement solution built with Decentriq's clean room technology, and an Identity Resolution Configurator. PurpleLab says the recognition reflects its work connecting healthcare media investment to real-world patient outcomes while preserving privacy.

    • PurpleLab was named a finalist in the 2026 AdExchanger Awards in the Best Measurement or Analytics Capability category, announced on September 25, 2026.
    • The finalists were selected by an independent panel of senior industry figures.
    • Over the past year, PurpleLab launched a full HealthNexus measurement suite with standalone APIs and custom services for end-to-end campaign measurement.
  • ·The DrumData Neutrality

    Neutrality has two tests, but vendors keep answering the easy one

    Erin Lutenski, Head of Marketing at Decentriq, discusses the industry's conflation of two distinct neutrality questions following data platform acquisitions. The first question concerns data exposure, which technical measures like encryption and trusted execution environments can address. The second, harder question concerns incentives: who decides product roadmaps, measurement standards, and partner integrations, and whether a parent company's commercial interests will compromise the platform's neutrality. Using LiveRamp's acquisition by Publicis and the earlier case of Acxiom's acquisition by IPG, Lutenski argues that vendors often provide technical reassurances that do not resolve the underlying incentive concerns. She contends that governance policies are reversible and architecture alone cannot ensure neutrality. The article concludes by urging stakeholders to identify which question a neutrality statement actually answers.

    • LiveRamp filed neutrality commitments with the SEC ahead of its acquisition by Publicis.
    • Publicis is acquiring LiveRamp.
    • LiveRamp was formed in 2018 after Acxiom split and IPG acquired Acxiom Marketing Solutions.
ViralGains Logo

ViralGains

Recent Signals

  • ·ViralGainsProduct & Platform Launch

    What Should Healthcare Advertisers Ask Patients? It Depends on the Disease State.

    ViralGains published a blog post on September 11, 2026, explaining that healthcare advertisers should ask different patient questions depending on the disease state and campaign goal. The post outlines example questions for rare disease, oncology, rheumatology, neurology, and chronic conditions to uncover context beyond traditional targeting signals. It highlights VG Health's capability to ask optional questions within digital advertising and use the responses to inform messaging and power VoiceAlike® AI for audience building.

    • ViralGains published the article on September 11, 2026.
    • The article provides example patient questions for rare disease, oncology, rheumatology, neurology, and chronic conditions.
    • VG Health lets healthcare marketers ask short, optional patient questions directly within digital advertising.

Start with a company or market. Track what changes.

Create your Polaris7 workspace to explore extended company profiles, organize relevant players into Watchlists, and receive focused briefings when material changes occur.